

1 **Supporting Information**

2

3 **Identification and Toxicological Evaluation of Unsubstituted PAHs**

4 **and Novel PAH Derivatives in Pavement Sealcoat Products**

5

6 Ivan Titaley,^a Anna Chlebowski,^b Lisa Truong,^b Robert L. Tanguay,^b and Staci L. Massey

7 Simonich^{a,b*}

8 ^aDepartment of Chemistry, Oregon State University, Corvallis, OR, 97331, USA

9 ^bDepartment of Environmental and Molecular Toxicology, Oregon State University, Corvallis,

10 OR, 97331, USA

11 *Corresponding Author (staci.simonich@oregonstate.edu), phone: (541) 737-9194,

12 fax: (541) 737-0497

13

14 **SI contains:**

15 18 pages

16 3 tables

17 6 figures

18 **Content:**

19 Sample Collection.....3

20 Sample Analysis.....4

21 Quality assurance/quality control (QA/QC)5

22 **Table S1.** Mean concentrations of individual PAH analyzed in this study for all samples6

23 **Figure S1.** Comparison of measured PAHs concentrations between USGS study (2012) and this

24 study10

25 **Table S2.** List of PAHs and MW302-PAHs in sealcoat products with their corresponding draft

26 RPF and PEF values.....11

27 **Table S3.** List of PAHs and MW302-PAHs in CT-1 time point scrapes with their corresponding

28 draft RPF and PEF values11

29 **Figure S2.** Nitro- and Oxy-PAHs derivative products concentration post sealcoat application...13

30 **Figure S3.** Direct and indirect acting Ames mutagenicity data of F1-F11 of all sealcoat products

31 analyzed at 1:100 dilution.....14

32 **Figure S4.** Direct and indirect acting Ames mutagenicity data of F1-F11 of CT-1 time point

33 scrapes analyzed at 1:100 dilution15

34 **Figure S5.** EC₅₀ concentration of pavement sealcoat products calculated from the Zebrafish

35 developmental toxicity testing data16

36 **Figure S6.** EC₅₀ concentration of CT-1 time point scrapes calculated from the Zebrafish

37 developmental toxicity testing data17

38 **Sample Collection**

39 CT-1 product was collected from a 125 mL jar of commercially available product that
40 was obtained from the commercial applicator during application.¹ CT-2 and AS products were
41 collected from 5 gallon buckets after they were first stirred with a wooden stick, similar to paint
42 stirrer. Each product was applied to a 12 square inches glass sheets that have been pre-cleaned
43 with methanol. The application was done with a new natural bristle paint brush and each glass
44 was dried in a dark room.

45 **Sample Analysis**

46 PAHs, MPAHs, and Hetero-PAHs were analyzed in electron impact ionization mode, and
47 NPAHs and OPAHs were analyzed in electron capture negative ionization mode with a
48 programmed temperature vaporization inlet (Gerstel, Germany) using previously described
49 methods.^{2,3} All analyses were run in selected ion monitoring mode with triplicate injections.
50 Limits of detection ranged from 0.005 to 1.3 mg [PAH]/kg sealcoat.

51 GC/MS analyses for all analytes, except MW302-PAHs, were performed using an
52 Agilent 6890 GC coupled with a 5973N mass selective detector and an Agilent DB-5MS
53 (30 m × 0.25 mm I.D. × 0.25 μm film thickness) capillary column. For the MW302-PAHs, an
54 Agilent DB-17MS (60 m × 0.25 mm I.D. × 0.25 μm film thickness) capillary column was
55 used.^{4,5} MW302-PAHs were also analyzed in electron impact ionization mode,⁴ but with a slight
56 modification to the oven programming that included a 45°C/min ramp to 200°C and a 15-min
57 isothermal hold at 320°C.

58 **Quality assurance/quality control (QA/QC)**

59 Field replicates were obtained by collecting scrapes from five different spots in the
60 parking lot.¹ Instrument replicates were obtained by triplicate injection for every analyzed
61 sample. The results given in Table S1 are derived from the mean of the triplicate injections. Our
62 results were compared to results from Van Metre, et al. (2012) (Figure S1). The limit of
63 detection (LOD) was estimated for each compound using a signal to noise ratio of 3:1. The limit
64 of quantitation (LOQ) was estimated for each compound using a signal to noise ratio of 10:1.

Sample	CT-1 (mg/kg)	CT-2 (mg/kg)	AS (mg/kg)	1.6 h (mg/kg)	1 d (mg/kg)	45 d (mg/kg)	149 d (mg/kg)	LOD (mg/kg)	LOQ (mg/kg)
NAP	1	130	1	1	4	1	0.5	0.005	0.02
ACY	4	5	<LOD	5	6	2	2	0.035	0.1
ACE	140	740	2.5	89	170	6	1	0.035	0.1
FLO	620	2,300	4.5	370	1,300	30	7	0.005	0.02
DBT	350	740	1	230	430	46	24	0.005	0.02
PHE	8,300	45,000	14	16,000	56,000	2,300	1,200	0.005	0.02
ANT	2,500	4,700	7	2,800	4,600	100	25	0.005	0.02
FLA	6,800	31,000	3	20,000	71,000	6,400	4,900	0.005	0.02
PYR	5,600	33,000	4	20,000	68,000	6,200	4,700	0.005	0.02
RET	10	5	2	10	9	4	<LOD	0.005	0.02
BcFlo	120	160	0.2	140	210	80	62	0.002	0.01
CPP	10	9	<LOD	3	4	2	7	0.005	0.02
BaA	2,400	2,800	0.8	4,000	15,000	1,300	770	0.005	0.02
CHR+TRI	1,600	1,300	3	3,100	3,700	1,500	1,400	0.003	0.01
BbF	2,700	2,500	2	5,400	4,600	2,100	2,300	0.005	0.02
BkF	1,100	900	0.04	2,000	1,900	890	940	0.005	0.02
Bj+eA	<LOD	2	<LOD	<LOD	<LOD	<LOD	<LOD	0.005	0.02
BeP	1,600	1,300	3	2,600	2,700	1,200	1,100	0.005	0.02
BaP	3,000	1,800	0.4	4,300	5,200	1,900	1,800	0.005	0.02
DBah+acA	71	30	<LOQ	40	52	19	27	0.005	0.02
IcdPY	1,500	970	0.7	1,000	2,300	610	750	0.005	0.02
BghiP	21	66	0.6	11	280	48	3	0.005	0.02
ANH	470	220	0.8	470	620	69	90	0.005	0.02
2-MNAP	8	140	4	8	9	<LOD	<LOD	0.035	0.1
1-MNAP	8	86	4	8	8	<LOD	<LOD	0.035	0.1
2,6-DMNAP	4	46	0.5	3	6	<LOD	<LOD	0.035	0.1
1,3-DMNAP	4	48	0.5	3	6	<LOD	<LOD	0.035	0.1


Sample	CT-1 (mg/kg)	CT-2 (mg/kg)	AS (mg/kg)	1.6 h (mg/kg)	1 d (mg/kg)	45 d (mg/kg)	149 d (mg/kg)	LOD (mg/kg)	LOQ (mg/kg)
2-MPHE	540	920	4	460	1,400	170	110	0.035	0.1
2-MANT	210	340	<LOD	110	250	18	<LOD	0.035	0.1
1-MPHE	320	500	1.4	270	480	92	62	0.035	0.1
3,6-DMPHE	46	63	3	44	59	18	15	0.006	0.02
1-MPYR	1,500	2,100	0.5	2,200	3,100	340	180	0.005	0.02
6-MCHR	58	46	2	48	76	27	22	0.005	0.02
N23bF	38	16	<LOD	50	36	25	32	0.035	0.1
DBae+bkF	370	120	<LOD	360	280	220	280	0.035	0.1
DBakF	200	68	<LOD	160	110	29	27	0.1	0.3
DBjIF	370	19	<LOD	650	490	350	500	0.05	0.2
DBalP	15	7	<LOD	13	8	1	1	0.05	0.2
N23kF	250	180	<LOD	460	310	77	130	0.5	1.7
N23eP	66	24	<LOD	72	54	41	47	0.035	0.1
DBaeP	160	46	<LOD	150	97	83	110	0.005	0.02
COR	120	36	<LOD	130	120	94	110	0.03	0.1
DBaiP	120	44	<LOD	80	61	38	44	0.05	0.2
DBahP	250	110	<LOD	69	41	25	29	0.1	0.3
2-MBF	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	0.004	0.01
THI	<LOD	4	<LOD	<LOD	<LOD	<LOD	<LOD	0.02	0.07
QUIN	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	0.008	0.03
IND	1	6	0.3	<LOD	<LOD	<LOD	<LOD	0.05	0.2
8-MQN	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	0.007	0.02
DBF	380	1,000	3	100	210	4	1	0.03	0.1
XAN	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	0.01	0.03
5,6-BQN	<LOD	7	<LOD	3	5	1	0.3	0.01	0.03
ACR	<LOD	1	<LOD	<LOD	<LOD	<LOD	<LOD	0.05	0.2
CARB	1,500	2,800	1	740	540	150	67	0.05	0.2
1-NN	<LOD	<LOQ	<LOD	<LOD	<LOD	<LOD	<LOD	0.007	0.02
2-NN	<LOD	0.3	<LOD	<LOD	<LOD	<LOD	<LOD	0.007	0.02

Sample	CT-1 (mg/kg)	CT-2 (mg/kg)	AS (mg/kg)	1.6 h (mg/kg)	1 d (mg/kg)	45 d (mg/kg)	149 d (mg/kg)	LOD (mg/kg)	LOQ (mg/kg)
2-NBP	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	0.007	0.02
3-NBP	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	0.007	0.02
4-NBP	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	0.05	0.2
3-NBF	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	0.01	0.03
5-NAC	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	0.02	0.07
2-NFL	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	0.007	0.02
9-NAN	1	<LOD	<LOD	0.07	1	<LOD	<LOD	0.01	0.03
9-NPH	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	0.004	0.01
2-NBT	0.4	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	0.05	0.2
3-NPH	<LOD	0.01	<LOD	<LOD	<LOD	<LOD	<LOD	0.001	0.003
2-NAN	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	0.002	0.01
2+3-NF	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	0.02	0.07
1-NP	<LOD	<LOD	<LOD	0.2	0.3	0.3	0.4	0.02	0.07
2-NP	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	0.2	0.05	0.2
2,8-DNDB	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	0.07	0.2
7-NBaA	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	0.007	0.02
1-NTR	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	0.007	0.02
6-NCH	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	0.02	0.07
3-NBENZ	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	0.05	0.2
2-NTR	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	0.02	0.07
1,3-DNP	<LOD	0.4	<LOD	<LOD	0.3	0.2	<LOD	0.05	0.17
1,6-DNP	3	<LOD	<LOD	3	5	3	<LOD	0.05	0.2
1,8-DNP	4	10	<LOD	6	4	2	2	0.05	0.2
6-NBaP	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	0.07	0.2
9-FLU	1	11	1	2	3	1	5	0.007	0.02
PHD	0.5	0.1	<LOD	<LOD	0.4	<LOD	<LOD	0.05	0.2
ANQ	13	31	1	18	120	2	190	0.007	0.02
2-MANQ	1	3	<LOD	5	13	1	190	0.007	0.02
BFLN	9	13	0.025	52	78	96	115	0.007	0.02

Sample	CT-1 (mg/kg)	CT-2 (mg/kg)	AS (mg/kg)	1.6 h (mg/kg)	1 d (mg/kg)	45 d (mg/kg)	149 d (mg/kg)	LOD (mg/kg)	LOQ (mg/kg)
BEN	1	0.5	<LOD	0.3	0.4	0.04	<LOD	0.007	0.02
ACQN	<LOD	<LOD	<LOD	<LOQ	<LOD	<LOD	<LOD	1.3	4.3
BQN+PQN	6	10	<LOQ	170	120	190	420	0.007	0.02
BPYN	<LOD	0.25	<LOD	0.1	4	1	<LOD	0.007	0.02
1,6-BPQN	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	0.13	0.4

66

67 **Table S1.** Mean concentrations (dry weight, $n = 3$) and estimated LOD's and LOQ's of all the compounds detected in pavement
68 sealcoat products and time point scrapes.




69
 70 **Figure S1.** Comparison of PAH and PAH derivatives concentrations in the CT-1 product by prior publication¹ and those measured for
 71 this study. Only compounds that were detected in both studies were included here. CHR and DBahA in prior publication¹ were
 72 compared to CHR+TRI and DBah+acA concentrations in this study, respectively. Error bars represented standard errors of triplicate
 73 injections.

Compounds Group	Compound	Assigned RPF Value (Draft U.S. EPA RPF) ⁶	B[a]P _{eq} concentration (mg/kg)			Assigned PEF Value (Health Canada PEF) ⁷	B[a]P _{eq} concentration (mg/kg)		
			CT-1	CT-2	AS		CT-1	CT-2	AS
PAHs	ANH	0.4	190	86	0.8	0.1	47	22	0.2
	ANT	0	0	0	0	NV	NV	NV	NV
	BaA	0.2	478	570	0.4	0.1	239	285	0.2
	BaP	1	2,950	1,850	0.9	1	2,950	1,850	0.9
	BbF	0.8	2,190	2,000	2.1	0.1	274	249	0.2
	BcFlo	20	2,370	3,100	25	NV	NV	NV	NV
	BghiP	0.009	0.2	0.6	0.01	0.01	0.2	0.7	0.006
	Bj+eA	60 (from Benz[j]aceanthrylene)	0	119	0	NV	NV	NV	NV
	BkF	0.03	33	27	0.002	0.1	110	90	0.004
	CHR+TRI	0.1 (from Chrysene)	160	128	0.4	0.01 (from Chrysene)	16	13	0.03
	CPP	0.4	4	3.6	0	0.1	1	0.9	0
	FLA	0.08	540	2,490	0.6	0.001	6.8	31	0.003
	DBah+acA	10 (from Dibenzo[a,h]anthracene)	710	304	0	1 (from Dibenzo[a,h]anthracene)	71	30	0
	IcdPY	0.07	102	68	0.06	0.1	146	97	0.07
PHE	0	0	0	0	0.001	8.3	45	0.02	
PYR	0	0	0	0	NV	NV	NV	NV	
		SUM	9,730	10,750	30.3	SUM	3,870	2,710	1.9
MW302-PAHs	DBaeF+bkF	0.9 (from Dibenzo[a,e]fluoranthene)	332	109	0	1 (from Dibenzo[a,e]fluoranthene)	370	121	0
	DBaeP	0.4	63	18	0	1	160	46	0
	DBahP	0.9	220	97	0	1	246	107	0
	DBaiP	0.6	74	26	0	1	125	44	0
	DBalP	30	461	200	0	100	1,540	667	0
	N23eP	0.3	20	7	0	NV	NV	NV	NV
		SUM	1,170	457	0	SUM	2,430	985	0
		TOTAL	10,900	15,320	30.3	TOTAL	6,310	3,700	1.9


74 **Table S2.** List of PAHs and MW302-PAHs with their corresponding draft RPF and PEF values. NV stands for ‘No Value’.

Compounds Group	Compound	Assigned RPF Value (Draft U.S. EPA RPF) ⁶	B[a]P _{eq} concentration (mg/kg)				Assigned PEF Value (Health Canada PEF) ⁷	B[a]P _{eq} concentration (mg/kg)			
			1.6 h	1 d	45 d	149 d		1.6 h	1 d	45 d	149 d
PAHs	ANH	0.4	1,130	1,840	40	10	0.1	47	62	7	9
	ANT	0	0	0	0	0	NV	NV	NV	NV	NV
	BaA	0.2	805	3,080	250	150	0.1	403	1,540	125	77
	BaP	1	4,300	5,170	1,900	1,800	1	4,300	5,170	1,900	1,800
	BbF	0.8	4,340	3,710	1,650	1,850	0.1	543	464	206	231
	BcFlo	20	2,730	4,180	1,600	1,240	NV	NV	NV	NV	NV
	BghiP	0.009	0.1	2.5	0.4	0.03	0.01	0.1	2.7	0.5	0.03
	Bj+eA	60 (from Benz[j]aceanthrylene)	0	0	0	0	NV	NV	NV	NV	NV
	BkF	0.03	60	60	27	28	0.1	197	187	89	94
	CHR+TRI	0.1 (from Chrysene)	310	370	150	140	0.01 (from Chrysene)	31	37	15	14
	CPP	0.4	1.2	1.5	0.7	2.6	0.1	0.3	0.4	0.2	0.7
	FLA	0.08	1,570	5,650	510	390	0.001	20	71	6	5
	DBah+acA	10 (from Dibenzo[a,h]anthracene)	400	515	190	270	1 (from Dibenzo[a,h]anthracene)	40	52	19	27
	IcdPY	0.07	70	160	40	50	0.1	101	225	61	75
PHE	0	0	0	0	0	0.001	16	56	2.3	1.2	
PYR	0	0	0	0	0	NV	NV	NV	NV	NV	
		SUM	15,700	24,700	6,370	5,960	SUM	8,440	12,050	4,040	3,600
MW302-PAHs	DBaeF+bkF	0.9 (from Dibenzo[a,e]fluoranthene)	325	250	195	250	1 (from Dibenzo[a,e]fluoranthene)	361	280	216	282
	DBaeP	0.4	60	40	33	43	1	146	97	83	109
	DBahP	0.9	63	37	23	26	1	69	41	25	29
	DBaiP	0.6	48	37	23	26	1	80	61	38	44
	DBalP	30	401	225	39	31	100	1,340	751	130	104
	N23eP	0.3	22	16	12	14	NV	NV	NV	NV	NV
		SUM	917	607	325	395	SUM	2,000	1,230	493	568
		TOTAL	16,600	25,300	6,690	6,350	TOTAL	10,440	13,280	4,530	4,170


75 **Table S3.** List of PAHs and MW302-PAHs with their corresponding draft RPF and PEF values. NV stands for ‘No Value’.




76
 77 **Figure S2.** Concentration of PAHs and MPAHs and their Nitro- and Oxy-PAHs derivative products post pavement sealcoat
 78 application.




79
 80 **Figure S3.** Mutagenicity data of F1-F11 for the pavement sealcoat products analyzed at 1:100 dilution. The blue shade illustrates the
 81 indirect acting mutagenicity and the light orange shade illustrates the direct acting mutagenicity. * denotes significance from negative
 82 control ($p < 0.05$). Error bars represent one standard deviation.



83
 84 **Figure S4.** Mutagenicity data of F1-F11 for time point scrapes analyzed at 1:100 dilution. The green shade illustrates the indirect
 85 acting mutagenicity and the purple illustrates the direct acting mutagenicity. * denotes significance from negative control ($p < 0.05$).
 86 Error bars represent one standard deviation.



87
 88 **Figure S5.** EC₅₀ concentration of pavement sealcoat products calculated based on the lowest effect level (LEL) of “any effect” in the
 89 zebrafish developmental toxicity test. Error bars represent standard errors and * denotes no toxicity observed (i.e. no calculated EC₅₀).



90
 91 **Figure S6.** EC₅₀ concentration of CT-1 time point scrapes calculated based on the lowest effect level (LEL) of “any effect” in the
 92 zebrafish developmental toxicity test. Error bars represent standard errors and * denotes no toxicity observed (i.e. no calculated EC₅₀).

Reference

- 94 (1) Van Metre, P. C.; Majewski, M. S.; Mahler, B. J.; Foreman, W. T.; Braun, C. L.; Wilson,
95 J. T.; Burbank, T. L. PAH Volatilization Following Application of Coal-Tar-Based
96 Pavement Sealant. *Atmos. Environ.* **2012**, *51*, 108–115.
- 97 (2) Wang, W.; Jariyasopit, N.; Schrlau, J.; Jia, Y.; Tao, S.; Yu, T.-W.; Dashwood, R. H.;
98 Zhang, W.; Wang, X.; Simonich, S. L. M. Concentration and Photochemistry of PAHs,
99 NPAHs, and OPAHs and Toxicity of PM_{2.5} During the Beijing Olympic Games. *Environ.*
100 *Sci. Technol.* **2011**, *45*, 6887–6895.
- 101 (3) Jariyasopit, N.; Zimmermann, K.; Schrlau, J.; Arey, J.; Atkinson, R.; Yu, T.-W.;
102 Dashwood, R. H.; Tao, S.; Simonich, S. L. M. Heterogeneous Reactions of Particulate
103 Matter-Bound PAHs and NPAHs with NO₃/N₂O₅, OH Radicals, and O₃ Under Simulated
104 Long-Range Atmospheric Transport Conditions: Reactivity and Mutagenicity. *Environ.*
105 *Sci. Technol.* **2014**, *48*, 10155–10164.
- 106 (4) Jia, Y.; Stone, D.; Wang, W.; Schrlau, J.; Tao, S.; Simonich, S. L. M. Estimated Reduction
107 in Cancer Risk Due to PAH Exposures if Source Control Measures During the 2008
108 Beijing Olympics were Sustained. *Environ. Health Perspect.* **2011**, *119*, 815–820.
- 109 (5) Schubert, P.; Schantz, M. M.; Sander, L. C.; Wise, S. A. Determination of Polycyclic
110 Aromatic Hydrocarbons with Molecular Weight 300 and 302 in Environmental-Matrix
111 Standard Reference Materials by Gas Chromatography/Mass Spectrometry. *Anal. Chem.*
112 **2003**, *75*, 234–246.
- 113 (6) U.S. EPA; Integrated Risk Information System. *Development of a Relative Potency Factor*
114 *(RPF) Approach for Polycyclic Aromatic Hydrocarbon (PAH) Mixtures: In Support of*
115 *Summary Information on the Integrated Risk Information System (IRIS)*;
116 RPA/635/R-08/012A; Washington, D.C., 2010.
117 http://cfpub.epa.gov/ncea/iris_drafts/recordisplay.cfm?deid=194584 (accessed June 1,
118 2015).
- 119 (7) Health Canada. *Federal Contaminated Site Risk Assessment in Canada, Part I: Guidance*
120 *on Human Health Preliminary Quantitative Risk Assessment (PQRA), version 2.0*;
121 Contaminated Sites - Reports and Publications; H128-1/11-632E-PDF; Minister of Health,
122 Government of Canada: Ottawa, Ontario, Canada, 2005. [http://www.hc-sc.gc.ca/ewh-
124 semt/pubs/contamsite/part-partie_i/index-eng.php](http://www.hc-sc.gc.ca/ewh-
123 semt/pubs/contamsite/part-partie_i/index-eng.php) (accessed February 19, 2016).